Issues In Antibiotics Antiinfectives Antimicrobials And Antivirals 2013 Edition

Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2012 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Immunopharmacology in a compact format. The editors have built Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Immunopharmacology in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Antibiotics, Antiinfectives, Antimicrobials, and Antivirals. The editors have built Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Antibiotics, Antiinfectives, Antimicrobials, and Antivirals in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2012 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Immunopharmacology in a compact format. The editors have built Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Immunopharmacology in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Antimicrobials. The editors have built Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Antimicrobials in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Antibiotics represent one of the most successful forms of therapy in medicine. But the efficiency of antibiotics is compromised by the growing number of antibiotic-resistant pathogens. Antibiotic resistance, which is implicated in elevated morbidity and mortality rates as well as in the increased treatment costs, is considered to be one of the major global public health threats (www.who.int/drugresistance/en/) and the magnitude of the problem recently prompted a number of international and national bodies to take actions to protect the public (http://ec.europa.eu/dgs/health_consumer/docs/road-map-amr_en.pdf: http://www.who.int/drugresistance/amr_global_action_plan/en/; http://www.whitehouse.gov/sites/default/files/docs/carb_national_strategy.pdf). Understanding the mechanisms by which bacteria successfully defend themselves against the antibiotic assault represent the main theme of this eBook published as a Research Topic in Frontiers in Microbiology, section of Antimicrobials, Resistance, and Chemotherapy. The articles in the eBook update the reader on various aspects and mechanisms of antibiotic resistance. A better understanding of these mechanisms should facilitate the development of means to potentiate the efficacy and increase the lifespan of antibiotics while minimizing the emergence of antibiotic resistance among pathogens.

The Drugs Don't Work - A Penguin Special by Professor Dame Sally Davies, the Chief Medical Officer for England 'If we fail to act, we are looking at an almost unthinkable scenario where antibiotics no longer work and we are cast back into the dark ages of medicine where treatable infections and injuries will kill once again' David Cameron, Prime Minister Resistance to our current range of antibiotics is the new inconvenient truth. If we don't act now, we risk the health of our parents, our children and our grandchildren. Antibiotics add, on average, twenty years to our lives. For over seventy years, since the manufacture of penicillin in 1943, we have survived extraordinary operations and life-threatening infections. We are so familiar with these wonder drugs that we take them for granted. The truth is that we have been abusing them: as patients, as doctors, as travellers, in our food. No new class of antibacterial has been discovered for twenty six years and the bugs are fighting back. If we do not take responsibility now, in a few decades we may start dying from the most commonplace of operations and ailments that can today be treated easily. This short book, which will be enjoyed by readers of An Inconvenient Truth by Al Gore and Bad Pharma by Ben Goldacre, will be the subject of a TEDex talk given by Professor Dame Sally Davies at the Royal Albert Hall. Professor Dame Sally C. Davies is the Chief Medical Officer for England and the first woman to hold the post. As CMO she is the independent advisor to the Government on medical matters with particular interest in Public Health and Research. She holds a number of international advisory positions and is an Emeritus Professor at Imperial College. Dr Jonathan Grant is a Principal Research Fellow and former President at RAND Europe, a not-for-profit public policy research institute. His main research interests are on health R&D policy and the use of research and evidence in policymaking. He was formerly Head of Policy at The Wellcome Trust. He received his PhD from the Faculty of Medicine, University of London, and his B.Sc. (Econ) from the London School of Economics. Professor Mike Catchpole is an internationally recognized expert in infectious diseases and the Director of Infectious Disease Surveillance and Control at Public Health England. He has coordinated many national infectious disease outbreak investigations and is an advisor to the European Centre for Disease Prevention and Control. He is also a visiting professor at Imperial College.

Issues in Patents and Intellectual Property: 2013 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Genetic Patents in a concise format. The editors have built Issues in Patents and Intellectual Property: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Genetic Patents in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Patents and Intellectual Property: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Combination Therapy against Multidrug Resistance explores the potential of combination therapy as an efficient strategy to combat multi-drug resistance. Multidrug resistance (MDR) occurs when microorganisms such as bacteria, fungi, viruses, and parasites are excessively exposed to antimicrobial drugs such as antibiotics, antifungals, or antivirals, and in response the microorganism undergoes mutations or develops different resistance mechanisms to combat the drug for its survival. MDR is becoming an increasingly serious problem in both developed and developing nations. Bacterial resistance to antibiotics has developed faster than the production of new antibiotics, making bacterial infections increasingly difficult to treat, and the same is true for a variety of other diseases. Combination therapy proves to be a promising strategy as it offers potential benefits such as a broad spectrum of efficacy, greater potency than the drugs used in monotherapy, improved safety and tolerability, and reduction in the number of resistant organisms. This book considers how combination therapy can be applied in multiple situations, including cancer, HIV, tuberculosis, fungal infections, and more. Combination Therapy Against Multidrug Resistance gathers the most relevant information on the prospects of combination therapy as a strategy to combat multridrug resistance and helping to motivate the industrial sector and government agencies to invest more in research and development of this strategy as a weapon to tackle the multidrug resistance problem. It will be useful to academics and researchers involved in the development of new antimicrobial or antiinfective agents and treatment strtategies to combat multidrug resistance. Clinicians and medical nurses working in the field of infection prevention and control (IPC) will also find the book relevant Explores strategic methods with investigation of both short- and long-term goals to combat multidrug resistance Presents a broad scope to understand fully the ways to apply combined therapy to multidrug resistance Provides an overview of combination therapy, but also includes specific cases such as cancer, tuberculosis, HIV and malaria